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The ATP-sensitive potassium (KATP) channel couples blood levels of glucose to insulin 
secretion from pancreatic ȕ-cells. KATP channel closure triggers a cascade of events that 
results in insulin release. Metabolically generated changes in the intracellular concentrations 
of adenosine nucleotides are integral to this regulation, with ATP and ADP closing the 
channel and MgATP and MgADP increasing channel activity. Activating mutations in either 
of the two types of KATP channel subunit (Kir6.2 and SUR1) result in neonatal diabetes 
mellitus, whereas loss-of-function mutations cause hyperinsulinaemic hypoglycaemia of 
infancy. Sulphonylurea and glinide drugs, which bind to SUR1, close the channel through a 
pathway independent of ATP and are now the primary therapy for neonatal diabetes mellitus 
caused by KATP channel mutations. Insight into the molecular details of drug and nucleotide 
regulation of channel activity has been illuminated by cryo-electron microscopy structures 
that reveal the atomic-level organisation of the KATP channel complex. Here, we review how 
these structures aid our understanding of how the various mutations in Kir6.2 (KCNJ11) and 
SUR1 (ABCC8) lead to a reduction in ATP inhibition and thereby neonatal diabetes mellitus. 




[H1] Introduction   
 
The ATP-sensitive potassium (KATP) channel has a central role in insulin secretion, because 
it couples the metabolism of the pancreatic ȕ-cell to its electrical activity1. At sub-stimulatory 
glucose concentrations, the ȕ-cell membrane potential is dominated by the KATP 
conductance, which holds the membrane at a hyperpolarised level. However, when blood 
levels of glucose rise, glucose is rapidly taken up by ȕ-cells and metabolised to ATP, which 
binds to the KATP channel, causing it to close. As a result, the ȕ-cell depolarises, leading to 
activation of voltage-gated calcium channels and an influx of calcium that triggers insulin 
granule release. The importance of the KATP channel in insulin secretion is exemplified by the 
fact that its mutation results in human disease. Loss-of-function mutations cause 
hyperinsulinaemic hypoglycaemia of infancy (BOX 1), which is characterised by persistent 
and unregulated insulin secretion and life-threatening hypoglycaemia. Conversely, gain-of-
function mutations impair insulin secretion and produce neonatal diabetes mellitus, which is 
defined as diabetes mellitus that presents within the first 6 months of life2. Because the KATP 
channel is also expressed in the brain, patients with functionally severe mutations can also 
exhibit neurological symptoms in addition to neonatal diabetes mellitus, a condition known 
as DEND syndrome [G]. Sulphonylurea drugs, such as glibenclamide, stimulate insulin 
secretion by bypassing the metabolic steps and binding to and closing the channel directly. 
They have now replaced insulin as the therapy of choice for neonatal diabetes mellitus 
caused by KATP channel mutations. 
 
Since 2017, cryo-electron microscopy [G] studies by several different groups have revealed 
the overall architecture of the KATP complex, and provided detailed information on the ATP 
and glibenclamide-binding sites3-9. Similarities and differences in these structures and their 
implications for nucleotide regulation have been reviewed elsewhere10. This Review 
considers how the various structures provide fresh insight into the mechanism of action of 
mutations that lead to neonatal diabetes mellitus, and briefly reviews work on the 
management this disease. 
  
 
[H1] Architecture of the KATP channel 
The ȕ-cell KATP channel is a large (~900 kDa) macromolecular complex that comprises four 
pore-forming Kir6.2 (KCNJ11) subunits and four regulatory SUR1 (ABCC8) subunits. Kir6.2 
is a typical inwardly rectifying K (Kir) channel that has two transmembrane segments linked 
by a pore loop, and intracellular N and C termini (Fig.1 a, b). The pore-helix contains the 
highly conserved selectivity filter TXGXG sequence in which the carbonyl backbones 
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coordinate the permeating K+ ions. Kir6.2 possesses binding sites for both ATP and 
phosphatidylinositol-4,5-bisphosphate (PIP2), which inhibit and activate the channel, 
respectively11,12. 
 
SUR1 belongs to the ABC superfamily of transporter proteins and is so-called because it 
binds sulphonylurea drugs172. Each SUR1 subunit contains three sets of transmembrane 
domains: TMD0, TMD1 and TMD2, where TMD1 and TMD2 form canonical ABC exporter 
domains (Fig.1 a, b). TMD0 and TMD1 are linked by a large cytosolic loop (the L0 or CL3 
linker), which has a key role in channel gating. The cytoplasmic loops following TMD1 and 
TMD2 each contain a nucleotide-binding domain (NBD). These associate with one another 
in a head-to-tail dimer to form two cytoplasmic nucleotide-binding sites (NBSs) at the 
interface. Occupancy of NBS2 by MgADP enhances the channel open probability [G] 13.    
 
The overall shape of the KATP channel complex was first identified at low resolution by 
electron microscopy14. Subsequent near-atomic resolution structures, solved by cryo-
electron microscopy, have revealed the overall architecture of the complex, and provided 
information on the ATP, sulphonylurea and glinide binding sites3-9. Kir6.2 forms a central 
tetrameric pore resembling that of other mammalian Kir channels. The pore is surrounded by 
the four SUR1 subunits, each in complex with one Kir6.2. All but one structure (which adopts 
a ‘quatrefoil’ arrangement6) resemble a ‘propeller’ shape (Fig.1c). The ‘quatrefoil’ model, 
which probably represents a different state, shows a large conformational rotation of each 
SUR1 that markedly changes the interface between SUR1 and Kir6.26. 
 
[H1] Nucleotide regulation of channel activity   
The regulation of KATP activity by adenine nucleotides is central to its ability to regulate 
insulin secretion.  This regulation is complex due to the existence of three distinct classes of 
ATP-binding site, one on each Kir6.2 subunit and two on each SUR1 subunit (making 12 
sites in total)3-9. Expression of a C-terminally truncated Kir6.2 in the absence of SUR1 
revealed that the inhibitory ATP-binding site lies on Kir6.2. The ability of Mg-nucleotides 
(such as MgATP and MgADP) to stimulate channel activity, on the other hand, resides with 
SUR115. The balance between activation and inhibition of the KATP channel by adenine 
nucleotides determines the level of channel activity in the cell. Regulation by both Kir6.2 and 
SUR1 nucleotide-binding sites is essential for correct channel function. This point is 
illustrated by the fact that loss of ATP inhibition causes neonatal diabetes mellitus whereas 
lack of Mg-nucleotide activation leads to HI2,16-18. Severe gain-of-function mutations can also 
produce developmental delay and epilepsy due to the expression of Kir6.2/SUR1 channels 
in brain neurones16.   
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[H1] Kir6.2 mutations 
The ATP-binding site on Kir6.2 has been well characterised by electrophysiology, molecular 
modelling and cryo-electron microscopy. Functional studies have shown that inhibition of 
channel activity does not require Mg2+, that ADP and AMP also inhibit the channel but with 
less potency than ATP, and that other purine and pyrimidine nucleotides (including 
guanosine triphosphate, inosine triphosphate and uridine triphosphate) are less effective 
than adenine nucleotides11,19-21. The addition of large groups (such as adenosine) to the ! 
phosphate of ATP does not impair channel inhibition, suggesting the terminal phosphate 
might be exposed21. Furthermore, ATP inhibition is enhanced if SUR1 is present.  For 
example, the IC50 [G] for ATP inhibition of Kir6.2 expressed in the absence of SUR1 is ~100 
µM, compared with 10 µM when SUR1 is also present15.  
 
The ATP-binding site on Kir6.2 lies at the interface between two Kir6.2 subunits and close to 
the L0 loop of SUR1 (Fig. 2a). In all structures determined to date, the ATP adopts an 
unusual conformation, with the phosphates curling back towards the adenine ring. As 
predicted21, the !-phosphate is exposed to the extracellular medium.  
 
While the resolution of the cryo-electron microscopy density (~3.3–3.6Å) does not allow 
precise determination of atomic level ATP–protein interactions, when combined with 
functional studies it provides an accurate model of the ATP-binding site. Fig.2b highlights 
residues that interact with ATP4. The major part of the binding pocket is contributed by the 
C-terminus of one subunit, and comprises a beta-sheet containing residues K185 and I182 
and a helical segment bearing residues Y330, F333 and G334. In addition, N48 and R50 
from the N-terminus of the adjacent subunit interact with ATP. The "-phosphate of ATP is 
coordinated by the backbone nitrogen of K185, and the "-phosphates and !-phosphates by 
the side chains of K185 and R50, respectively. Residues I182 and Y330 lie close to the 
ribose moiety, and the adenine ring interacts with N48, R50 and Y330. Mutations in all these 
residues give rise to neonatal diabetes mellitus and impair ATP inhibition (Table 1). The 
interaction between the NH2 moiety at position 6 of the adenine ring and the backbone of 
N48 seems to be critical for selective nucleotide binding, as neither inosine triphosphate nor 
purine riboside-5’-O-triphsophate (which lack the critical NH2) are effective at inhibiting the 
channel21. 
 
In addition, residues in the L0 linker of SUR1 either contribute directly to ATP binding, or lie 
in close proximity to it and stabilise the binding pocket. In a recent structure with bound 
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ATP!S, SUR1–K205 interacts with the "-phosphates and "-phosphates of ATP8 (Fig.2c). 
Mutations at this position impair the channel ATP sensitivity8,22, which might explain how 
SUR1 enhances ATP inhibition in the absence of Mg2+ [ref 15]. Furthermore, E203 in SUR1 
interacts with Q52 in Kir6.2 and an engineered interaction between these residues results in 
channels with enhanced ATP sensitivity22. 
 
Multiple residues in Kir6.2 (>70) are known to cause neonatal diabetes mellitus (Fig.3; Table 
1). These include all the residues that participate in ATP binding (see previous discussion) 
and others that lie in close proximity (such as H46, E51, Q52 and G53 in the N-terminus). 
Substitution of a negative charge at G334 (G344D) almost totally abolishes ATP inhibition, 
and causes a severe form of neonatal diabetes mellitus that is associated with neurological 
dysfunction23. Different mutations at R50 cause variable degrees of impairment of ATP 
sensitivity and disease severity, with R50Q causing transient neonatal diabetes mellitus and 
R50P giving rise to DEND syndrome24. The most commonly mutated residue in permanent 
neonatal diabetes mellitus is R201, but the structures show this residue does not interact 
with ATP. Instead, it is probably responsible for stabilising the backbones of F333 and V316, 
whilst also potentially forming cation-pi interactions with both F333 and F315. Its mutation 
would therefore destabilise the structure of this region, repositioning the sidechain of F333 
and thereby impairing ATP binding. 
 
Another class of neonatal diabetes mellitus mutations in Kir6.2 act by increasing the intrinsic 
open probability of the channel and/or the conformational relay by which ATP binding is 
translated into pore closure. These residues lie at the membrane interface within the slide 
helix that precedes TM1, in the lower part of TM2 (for example, W68 or V59M)25-26,  within 
the gating loops that reside below the mouth of the pore (T293)27, and at the interface 
between subunits (for example, E322 and E292)28-29 (Fig.3). Several of these mutations 
increase the intrinsic channel open probability and thereby indirectly also reduce the 
apparent affinity for ATP. The most common is V59M, which causes DEND syndrome16,26. 
Studies have shown an exponential relationship between the channel open probability and 
ATP inhibition, with a further dramatic fall in ATP sensitivity when the channel open 
probability exceeds ~0.8 [ref 173].   
 
[H1] SUR1 mutations 
The NBSs of SUR1 contribute to the nucleotide regulation of KATP channel activity. Each 
NBS consists of a canonical Walker A and B motif contributed by one NBD and the ABC 
signature motif of the other NBD (Fig.4a). The two binding sites are distinct, with NBS2 
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being a consensus site (capable of ATP hydrolysis) and NBS1 being a degenerate site 
(incapable of hydrolysis)31. It is proposed that occupancy of NBS2 by MgADP induces a 
conformational change that leads to closure of the NBS dimer (Fig.4b), and results in further 
conformational changes that produce opening of the Kir6.2 pore174.    
 
Initial approaches to determine Mg-nucleotide binding to SUR1 used photoaffinity labelling 
with azido-ATP [ref 31]. Subsequently, a method was developed to enable ATP binding to 
be studied at high temporal and spatial resolution in native membranes32. This technique 
involves measuring FRET [G] between a genetically engineered fluorescent amino acid 
(ANAP), placed close to the ATP-binding site, and fluorescent nucleotides (TNP–ATP and 
TNP–ADP). It was found that binding of both ATP and ADP to NBS2 is Mg2+-independent, 
but that Mg2+ is required to trigger a conformational change in SUR1. Nucleotide dissociation 
was accelerated by the sulphonylurea tolbutamide (even in the presence of Mg2+) and 
slowed by the K+ channel opener diazoxide32. These findings are consistent with an 
activation model for KATP in which the NBDs of SUR1 dimerize in the presence of Mg2+, 
preventing rapid nucleotide dissociation and triggering a conformational change that is 
communicated to the channel pore (Fig.4b)32. Sulphonylureas prevent this dimerization, as 
predicted from the structures4,7,8, whereas K-channel openers stabilize it.  
 
Numerous mutations associated with neonatal diabetes mellitus are found in SUR1 (Fig.5; 
Table 2), but in many cases their functional effects have not been studied. Although these 
mutations are found throughout the protein, two major clusters are evident, one in NBS2 and 
another in the L0 linker. There are three ways in which these SUR1 mutations could affect 
nucleotide regulation of Kir6.2: they might enhance MgADP stimulation33,34, they might 
increase the intrinsic open probabability35, or they might impair ATP binding at Kir6.2.  
 
Functional studies support the idea that mutations in NBS2 that cause neonatal diabetes 
mellitus enhance occupancy by MgADP and/or stabilize the conformational change by which 
MgADP binding leads to an increase in the channel open probability33-38.  In the ȕ-cell, it is 
probable that the MgADP-bound state will be entered via hydrolysis of MgATP, which is 
present at much higher concentrations than MgADP. Thus, both the rate of ATP hydrolysis 
and the off-rate of MgADP will influence the duration of MgADP occupancy at NBS2. 
Functional analysis reveals the R826W mutation causes the ATPase cycle to linger in the 
post-hydrolytic MgADP.Pi-bound state (associated with channel activation) and that R1380 
enhances the hydrolytic rate34,36. Increased MgADP activation partially compensates for ATP 
inhibition at Kir6.2, resulting in increased current at a given MgATP concentration.  
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A second hotspot of neonatal diabetes mellitus mutations is located on the L0 loop of SUR1 
(19 mutations), and encompasses residues 206–215 (Fig.5; Table 2). Given that these 
residues lie in close proximity to the ATP-binding site on Kir6.2, they could help stabilise the 
binding pocket and their mutation might abrogate this interaction. It is also possible that 
many of these mutations also act by increasing the intrinsic channel open probability.  
 
Very few SUR1 mutations cause DEND syndrome. An exception is F132L, which acts by 
increasing the channel open probability35. Interestingly, in the structures, SUR1–F132 is 
close to Kir6.2–G53 and Kir6.2–V59, which also cause DEND syndrome when mutated35,39. 
Quite how mutations elsewhere in SUR1 influence nucleotide regulation is unclear and 
requires further study.  
 
 
[H1] Neonatal diabetes mellitus 
In Europe, the incidence of neonatal diabetes mellitus varies between ~1 in 90,000 live 
births in Italy and Germany to 1 in 161,000 in Austria 40-45. In populations with a high 
consanguinity rate, the prevalence can be even higher than this. For example, in north-west 
Saudi Arabia the incidence is ~1 in 20,00046.    
 
While mutations in many different genes result in neonatal diabetes mellitus, gain-of-function 
mutations in either Kir6.2 or SUR1 are the most common cause (~40% of cases, depending 
on the population)40,42. These mutations result in KATP channels that have reduced sensitivity 
to inhibition by ATP and thus remain open despite elevated blood levels of glucose. 
Consequently, insulin secretion is impaired, resulting in blood levels of glucose that are 
chronically elevated106. In some patients, the diabetes mellitus resolves within a few months 
or years, only for it to recur later in life (a condition referred to as transient neonatal diabetes 
mellitus)41,47. In other cases, the diabetes mellitus is permanent. Although the majority of 
cases present within the first 6 months of life, diabetes mellitus occasionally presents in the 
post-neonatal period41,51; it remains possible, however, that these individuals had transient 
neonatal diabetes mellitus that was undiagnosed in early life. 
 
Around ~20–30% of patients have neurological symptoms48, which include developmental 
delay, muscle hypotonia, autism and attention deficit hyperactivity disorder, as well as 
neonatal diabetes mellitus. This condition is known as intermediate (or incomplete) DEND 
syndrome. A few patients (<5%) have full DEND syndrome, in which the characteristics of 
intermediate DEND syndrome are also accompanied by epilepsy. The neurological features 
are a consequence of the fact that KATP channels are expressed in brain neurones49,50.  
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There is a reasonably good correlation between the ability of a given mutation to reduce the 
ATP sensitivity of the channel and the clinical phenotype, with mutations that produce the 
greatest reduction in ATP inhibition causing DEND syndrome17. The reason only the most 
severe mutations produce dysfunction of the central nervous system is presumably because 
a greater increase in KATP channel activity is needed to influence electrical activity in 
neurones than in the ȕ-cell.  
 
Almost all patients with Kir6.2 mutations are heterozygous for the mutation. The exception is 
G324R, which causes neonatal diabetes mellitus in the homozygous, but not heterozygous, 
state52. The difference in ATP sensitivity between homozygous and heterozygous Kir6.2–
G324R channels is remarkably small (IC50 of 38 µM and 30 µM, respectively) and not much 
greater than that of wild-type channels (20 µM)52. Thus, tiny changes in ATP sensitivity can 
cause neonatal diabetes mellitus. This finding is not surprising given that close to the 
threshold potential at which electrical activity is initiated, the ȕ-cell membrane potential is 
exquisitely sensitive to the magnitude of the KATP current and a tiny decease in current will 
lead to action potential firing and thus insulin release53. 
 
Genome wide association studies have shown that a common variant in Kir6.2 (E23K) is 
associated with a small, but highly significant increase in the risk of type 2 diabetes mellitus 
(K allele, odds ratio 1.23, P = 0.000015; KK genotype odds ratio 1.65, P = 0.000002)54.  
Functional studies have also shown that in people with normal glucose tolerance, the ‘at risk’ 
lysine (K) allele is associated with a marked (40%) reduction in insulin secretion in response 
to an oral or intravenous glucose challenge55. Precisely how the K variant leads to impaired 
insulin release in later life has long been debated. The measured reduction in ATP sensitivity 
is small, often not statistically significantly different from wild-type and has not been 
replicated in all labs52,55,56. It has also been argued that the E23K mutation itself is not causal 
but rather a linked mutation in SUR1, A1369S [ref 56]. However, the tiny difference in ATP 
sensitivity between homozygous and heterozygous G324R channels suggests that a 
reduction in ATP sensitivity that predisposes to diabetes mellitus later in life can be hard to 
detect in electrophysiological experiments, except when very large sample sizes are used. It 
also explains why people with the K variant do not develop diabetes mellitus at birth — the 
reduction in ATP sensitivity contributed by this variant is too small. Whether they do so in 
later life might depend on their genetic background as well as environmental factors such as 




[H1] Inhibition of the KATP channel 
Sulphonylureas (for example, glibenclamide) and glinides (for example, repaglinide) are 
antidiabetic drugs that stimulate insulin secretion by inhibiting KATP channel activity. Analysis 
of cryo-electron microscopy structures obtained in the presence of glibenclamide or 
repaglinide indicate that sulphonylurea and glinide drugs bind within the same pocket, which 
lies within the transmembrane domains of SUR1 [ref 4,7,8,9]. Glibenclamide binding is 
coordinated by the inner helices of TMD1 (TMs 6, 7 and 8) and TMD2 (TM16), with which it 
forms both polar and electrostatic interactions. Both glibenclamide and repaglinide interact 
with two arginine residues — R1246 and R1300 [ref 4,7,8,9]. However, there are some 
subtle differences in the binding sites. For example, glibenclamide lies too close to S1238, 
which was previously shown to form part of the sulphonylurea binding site and accounts for 
the difference in drug affinity between SUR1 and SUR2 [ref 57]. This residue, however, does 
not contribute to repaglinide binding8,9, as predicted from functional studies58. 
 
Sulphonylurea inhibition of the KATP channel is complex. The drug has a direct inhibitory 
effect on channel activity, which results in a maximal block of between 60–80% (depending 
on the specific sulphonylurea)59. In addition, sulphonylurea binding displaces bound MgATP 
at NBS2, promoting dissociation of the NBDs, which reduces channel activation by MgATP 
and/or MgADP and unmasks ATP inhibition at Kir6.232. In practice, this means that neonatal 
diabetes mellitus mutations that strongly reduce the channel ATP sensitivity also reduce 
sulphonylurea inhibition. This finding explains why patients with the Kir6.2–G334D mutation 
do not respond to drug therapy60. A few mutations that cause neonatal diabetes mellitus 
(including Kir6.2–C166F and Kir6.2–I296L) dramatically decrease the time that the channel 
spends in a long closed state61-63. As sulphonylureas produce KATP channel inhibition by 
stabilizing this state64, these mutations also greatly reduce sulphonylurea inhibition26,60,65.  
  
 
[H1] Sulphonylurea therapy 
The discovery that many cases of neonatal diabetes mellitus are caused by mutations in 
Kir6.2 or SUR1 has transformed therapy for these patients. Previously treated by insulin 
injections, more than 90% of patients are now managed on oral sulphonylurea therapy66-68, 
which greatly improves their quality of life and management of their disease. Glycaemic 
control is also markedly improved, reducing the risk of diabetic complications.  
 
Of particular importance is that sulphonylurea therapy restores the insulin secretory 
response to food or an oral glucose challenge66,68. Incretins, such as GLP1, which are 
released in response to the presence of food in the gut, are effective stimulators of insulin 
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secretion1. However, they are only effective at glucose concentrations at which KATP 
channels are largely closed69. This is because they produce a small depolarising current that 
is only able to stimulate ȕ-cell electrical activity when the KATP conductance is very low70,71, 
and/or they amplify the effect of intracellular calcium on exocytosis (which depends on ȕ-cell 
electrical activity)1,71. They can also cause a small reduction in the KATP current that, by itself, 
is insufficient to trigger electrical activity72.  
 
Sulphonylurea therapy in type 2 diabetes mellitus is often associated with hypoglycaemia 
and weight gain. However, there is no reported increase in hypoglycaemic episodes or body 
mass index in patients with neonatal diabetes mellitus who are treated with sulphonylureas, 
despite the high drug doses needed to control blood levels of glucose68. This implies that 
KATP channel closure induced by therapeutically effective sulphonylurea concentrations in 
patients with neonatal diabetes mellitus is sufficient to bring the ȕ-cell membrane potential 
close to threshold, but is not enough to elicit electrical activity by itself. This is achieved in 
response to a meal by both incretins and any remaining sensitivity of the channel to 
metabolically generated ATP106.   
 
Not all patients with neonatal diabetes mellitus are able to transfer to sulphonylurea therapy. 
A successful outcome is determined both by the specific mutation and by the duration of 
diabetes mellitus73. As explained above, some KATP channel mutations can affect 
sulphonylurea efficacy. In addition, patients who commence sulphonylureas in the first few 
years after diagnosis are far more likely to successfully transfer than those who do so after 
diabetes mellitus of longer duration. Evidence from animal models suggests this is because 
chronic exposure to hyperglycaemia has deleterious effects on the ȕ-cell: insulin content is 
reduced and mitochondrial metabolism impaired so that insufficient ATP is generated in 
response to a glucose stimulus74-76. These effects are reversible if the diabetes mellitus is of 
short duration, but high drug concentrations are needed when the disease duration is 
prolonged75. The fact that the sulphonylurea dose decreases with the duration of therapy in 
patients with neonatal diabetes mellitus68 might be due to improved ȕ-cell function and 
increased insulin content when good control of glycaemia is established. Preservation of ȕ-
cell function can also account for the fact that minimal dosing is needed in some patients 
when sulphonylurea treatment is initiated early77. 
  
In some individuals, the insulin dose can be reduced when sulphonylureas are introduced, 
but cannot be discontinued completely. It is recommended that both insulin and 
sulphonylurea are used to treat these patients78. In contrast to type 2 diabetes mellitus, 
where sulphonylurea failure is observed in ~44% of individuals after 5 years of treatment79, 
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excellent glycaemic control remained after 10 years of sulphonylurea therapy in all patients 
with KATP mutations examined68.  Thus, sulphonylureas remain the therapy of choice for this 
group of patients.  
 
Neurological dysfunction is found in many patients with neonatal diabetes mellitus. During 
the past few years it has become evident that despite some initial improvement68,80,81, central 
nervous system dysfunction persists with long-term sulphonylurea therapy. One possible 
explanation is that therapeutic drug concentrations are not reached in the brain because of 
active efflux across the blood–brain barrier82. Single photon emission computed tomography 
scans of the brain of patients with neonatal diabetes mellitus before and after glibenclamide 
therapy show changes in activity after ~6 months of therapy, but these are confined to the 
cerebellum83. Another possibility is that overactivity of KATP channels at an early 
developmental stage results in permanent neurological changes. It is noteworthy that for 
both glycaemic control and neurological function, the best outcome is achieved when drug 
therapy is commenced early. Further research in this area is clearly needed.  
 
Pre-natal diagnosis is valuable for determining the optimal management of pregnant women 
with a KATP channel mutation because sulphonylureas can cross the placenta and cause 
macrosomia and neonatal hypoglycaemia in babies who do not carry the mutation84. On the 
other hand, a child with the same mutation might benefit from early exposure to the drug. 
Non-invasive pre-natal diagnosis has been successfully used to determine if the fetus 
carries a mutation in the KATP channel85. Sulphonylureas can also enter breast milk84, which 




The past few years have seen marked advances in our knowledge of the KATP channel and 
the relationship between channel structure and function. Atomic resolution structures have 
shown in considerable detail where ATP and antidiabetic drugs bind. With some exceptions, 
these structures have largely confirmed what was known of the nucleotide-binding sites from 
functional studies. By contrast, the sulphonylurea-binding and glinide-binding site was 
previously unidentified. What remains unclear is how nucleotide or drug binding is translated 
into changes in channel activity and how conformational changes in SUR1 lead to altered 




In parallel, our understanding of how KATP channel mutations cause neonatal diabetes 
mellitus, and of sulphonylurea therapy in neonatal diabetes mellitus, has also progressed. 
Both structural and functional studies have illuminated how disease-causing mutations 
produce their functional effects. It is also now clear that patients can be managed for many 
years with no loss of glycaemic control68, that hypoglycaemic episodes are rare68 and that 
sulphonylureas can cross the placenta84. Functional studies in mouse models of neonatal 
diabetes mellitus suggest the reason older patients have a lower frequency of transfer to 
drug therapy than younger ones is due to adverse effects of chronic hyperglycaemia on ȕ-
cell function74-76. Future studies can be expected to address the mechanisms by which 
chronic hyperglycaemia impairs ȕ-cell function and how this might be ameliorated, and 
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BOX 1: Mechanism of action of hyperinsulinaemic hypoglycaemia of infancy 
mutations  
 
Given that gain-of-function mutations in KATP channel genes result in too little insulin 
secretion, and thus neonatal diabetes mellitus, it comes as no surprise that loss-of-function 
mutations in either KCNJ11 or ABCC8 lead to hypersecretion of insulin (congenital 
hyperinsulinism or HI)2,18. Hyperinsulinaemic hypoglycaemia of infancy mutations produce 
reduced KATP channel activity: consequently, the ȕ-cell membrane is permanently 
depolarised and insulin is continuously released. The resulting low blood levels of glucose 
can cause irreversible brain damage if it is not promptly treated86. Although mutations in 
multiple genes can cause HI2,18, the most commonly affected are KCNJ11 and ABCC8.  
 
Unlike neonatal diabetes mellitus, the functional effects of many KATP channel HI mutations 
remain to be investigated. Among those that have been studied, many result in the protein 
not being made or trafficked to the plasma membrane87. These mutations therefore do not 
offer insight into KATP channel gating or nucleotide regulation. Other HI mutations give rise to 
channels that traffic to the surface membrane and are briefly considered here. These mutant 
channels either have a low intrinsic open probability or are no longer activated by PIP2 (via 
Kir6.2) or by MgATP and MgADP (via SUR1; Box figure 1). In Kir6.2, these residues lie in 
regions of the channel concerned with gating (for example, F55L88, T29427) or around the 
putative PIP2-binding site (for example, K6789). Molecular modelling studies suggest that 
K67 interacts with the phosphate group of PIP2, which is consistent with functional studies 
that suggest the K67L mutation reduces PIP2 binding90. Mutations at R301 are also 
proposed to act by destabilising the interaction of Kir6.2 with PIP291. Some HI mutations, 
located in SUR1, impair the mechanism by which Mg-nucleotides stimulate channel 
activity13,37 but further research is needed to determine if they affect MgATP or MgADP 
binding, ATP hydrolysis or the conformational change that translates binding into channel 
opening.  
 
Box 1 Figure. Location of Kir6.2 and SUR1 residues mutated in HI. a. Kir6.2 tetramer 
showing residues mutated in HI as blue sticks and ATP in CPK colours. Only mutations 
known to result in channels that are trafficked to surface membrane are shown. b. Single 
SUR1 subunit showing residues mutated in hyperinsulinism as blue spheres. Only mutations 








Figure 1: Structure of the KATP channel complex. a. Transmembrane topology of Kir6.2 
and SUR1. For clarity, only a single SUR1 subunit and two opposing Kir6.2 subunits are 
shown. b. Side-view of the cryoEM structures of the Kir6.2 tetramer (green) and a single 
SUR1 subunit (PDB accession number 6BAA). SUR1 is colour-coded, with TMD0 in purple, 
L0 in orange, TMD1 in yellow and TMD2 in blue. The dashed line shows the approximate 
location of the membrane. c,d. Top view of the propeller (c) and quatrefoil (d) structures of 
the KATP channel complex (PDB accession numbers 6BAA and 63CO, respectively). Same 
colour code as in b. Panels adapted with permission from reference 10. 
 
Figure 2. The inhibitory ATP-binding site. a. Top view of the KATP tetramer showing the 
four ATP-binding sites on Kir6.2. Each Kir6.2 subunit is shown in a different colour, residues 
200–240 in L0 of SUR1 are in blue and ATP is in CPK colours. PDB accession number 
6BAA. b. Close-up of the ATP-binding site, showing residues that participate in ATP binding. 
These are colour-coded according to the Kir6.2 subunit they come from. PDB accession 
number 6BAA. c. Close-up of the ATP-binding site, showing residues that participate in ATP 
binding, which are colour-coded according to the Kir6.2 subunit they come from. The 
structure was obtained in the presence of ATP!S. PDB accession number 6JB1. 
  
Figure 3. Location of Kir6.2 residues mutated in neonatal diabetes mellitus. Kir6.2 
tetramer showing residues mutated in neonatal diabetes mellitus as red sticks. ATP is 
shown as CPK spheres. The dashed line shows the approximate location of the membrane.  
  
Figure 4. The nucleotide-binding sites on SUR1. a. The stimulatory nucleotide-binding 
sites on SUR1 are formed at the interface of NBD1 (green) and NBD2 (lilac). The Walker A 
motif is shown in magenta, the Walker B motif in blue and the ABC signature sequence in 
yellow. MgATP is shown bound to NBS1 and MgADP to NBS2. PDB accession number 
6C3P. b. Schematic for activation of the KATP channel complex by Mg-nucleotides. Top left. 
In the absence of Mg2+, ADP rapidly binds and unbinds to SUR1, but has no effect on 
channel activity. Top right. The presence of Mg2+ causes NBD dimerization, which induces a 
conformational change that leads to opening of the Kir6.2 pore. Bottom Left. Binding of 
sulphonylureas to SUR1 causes dimer dissociation and prevents MgADP stimulation. 
Bottom Left. Binding of K-channel openers to SUR1 stabilises the NBD dimer and supports 




Figure 5. Location of SUR1 residues mutated in neonatal diabetes mellitus. Single 


















NTD L2P NDM - - - 92 
NTD S3C PNDM - - Yes 73 
NTD E23K and 
I337V 
T2DM risk - - - 54,93 
NTD R27H Adult onset  - Yes Yes 93 
NTD A28–R32 
deletion 
PNDM No Yes - 94 
NTD F33I NDM - - Yes 68 
NTD R34C NDM - - - 41 
NTD F35L PNDM Yes Yes - 95,96 
NTD F35V PNDM Yes Yes Yes 66,95 
NTD K39R NDM - - Yes 97 
NTD C42R TNDM Yes Yes Yes 73,98,
99 
NTD H46L iDEND - Yes Yes 73,100
,101 
NTD H46R NDM - - - 102 
NTD H46Y PNDM No Yes Yes 29,40,
66,73 
NTD N48D TNDM - Yes - 29 
NTD N48I PNDM - - - 102 
NTD R50G DEND - - - 103,10
4 
NTD R50P DEND and/or 
iDEND 
No Yes Yes 24,73,
99,105 
NTD R50Q TNDM and/or 
PNDM 
- Yes Yes 24,66,
73,99,
103 
NTD E51A PNDM - - Yes 73 
NTD Q52R DEND Yes Yes Some 65,26,
73,106
,107 
NTD Q52L iDEND and/or 
PNDM 
- - Yes 108 
NTD G53D PNDM, iDEND 
and/or DEND 





NTD G53N PNDM - - Yes 66,96 
TM2 G53R TNDM and/or 
iDEND 
No Yes Yes 39,47,
73 
NTD G53S TNDM Yes Yes Some 39,47,
73 
NTD G53V TNDM - - - 104,11
0 
Slide helix V59A DEND - - Some 42,99,
111 
Slide helix V59G DEND Yes Yes - 26,106 
Slide helix V59M iDEND Yes Yes Some 26,65,
66,73,
99,106 
Slide helix F60Y DEND Yes Yes Yes 25,73 
Slide helix V64M DEND - - - 99 
Slide helix W68R TNDM Yes Yes Yes 73,112 
Slide helix W68L PNDM - Yes Yes 112,11
3 
Slide helix W68G PNDM - Yes Yes 112,11
3 
Slide helix W68C PNDM - Yes - 92,112 
TM2 A161T TNDM - - Yes 73 
TM2 L164P PNDM Yes Yes No 40,66,
73,114 
TM2 C166F DEND Yes Yes - 61,62 
TM2 C166Y DEND - - No 40,73 
TM2 I167F DEND - - Yes 115 
TM2 I167L DEND Yes Yes Yes 116 
TM2 K170N iDEND - - Yes 73,104
,105 
TM2 K170R PNDM - - Yes 73,104
,105 
TM2 K170T PNDM No Yes Yes 28,40,
66,73 
TM2 A174G TNDM - - - 103 
CTD E179A NDM - - - 41 
CTD I182T PNDM - - - 104 
CTD I182V TNDM - Yes - 47,104 
CTD K185Q PNDM - Yes Yes 104,11
7 
CTD K185T NDM - - Yes 73 
CTD H186D PNDM - - Yes 118 
 29
CTD R192H Adult onset - Yes Yes 93 
CTD R201C iDEND No Yes Some 26,66,
73,106 
CTD R201G PNDM - - Yes 99 
CTD R201S NDM - - Yes 42,73 
CTD R201H PNDM No Yes Some 66,73,
96,106
,107 
CTD R201L PNDM - - Yes 66,73 
CTD S225T + 
P226-P232 
deletion 
iDEND Yes Yes Yes 119,12
0 
CTD E227L TNDM, adult 
onset 
 - Yes Yes 121 
CTD E227K TNDM and/or 
PNDM 
Yes Yes Yes 29,73,
99 
CTD G228A NDM - - - 122 
CTD E229K TNDM Yes Yes Yes 29,73 
CTD V231L + 
G324R 
NDM - - - 102 
CTD L233F NDM - - Yes 73,123 
CTD V252A TNDM and/or 
PNDM 
- Yes - 29,104 
CTD V252G iDEND - - - 104 
CTD V252L NDM - - Yes 124 
CTD V252M PNDM - - Yes 73,104 
CTD P254Q TNDM - - - 125 
CTD V285I TNDM - - - 126 
CTD E292G PNDM - Yes - 29 
CTD T293N iDEND and/or 
DEND 
Yes Yes Yes 27,99 
CTD I296L DEND Yes Yes No 63,65,
66,73,
106 
CTD E322K PNDM No Yes Yes 28,66,
73,96 
CTD E322A + 
D352H 
TNDM - - Yes 127 
CTD G324R TNDM - Yes Yes 52 
CTD G324R + 
V231L 
NDM - - - 102 
 30
CTD Y330C PNDM Yes Yes - 96,128
,129 
CTD Y330S PNDM - - Yes 40,66,
73 
CTD F333I PNDM No Yes Yes 73,128
,129 
CTD F333L PNDM - - Yes 130 
CTD G334C PNDM - - Some 73,104 
CTD G334D DEND No Yes No 23,104 
CTD G334V PNDM - Yes Yes 78 
CTD I337V + E23K T2D risk - - - 54,93 
CTD D352H + 
E322A 
PNDM - - Yes 127 
CTD G366W NDM - - - 131 
 
 
Mutations in Kir6.2 associated with neonatal diabetes mellitus. The effects on channel 
activity, determined from electrophysiology, are indicated where known. All mutations are 
dominant (heterozygous) except for G324R. NTD, N-terminal domain; CTD, C-terminal 
domain; TM2, transmembrane helix 2; PNDM, permanent neonatal diabetes mellitus; TNDM, 
transient neonatal diabetes mellitus; NDM, neonatal diabetes mellitus; Po, open probability; 
Adult onset, adult onset diabetes; T2DM, type 2 diabetes mellitus; SU, sulphonylurea (a 
response to SU therapy is defined as patients who require no, or less, insulin when treated 






























TMD0 I49F DEND - - Yes het 135,
136 
TMD0 N72S PNDM  -  - No mosaic 133,
134,
137 
TMD0 V84I Adult onset  -  -  - het 138 
TMD0 V86A PNDM  -  - Yes het 126,
133,
134 
TMD0 V86G PNDM  -  - Yes het 133,
134 
TMD0 A90V PNDM  -  -  - het 103 




TMD0 E100K Adult onset 
(MODY) 
 -  - Yes het 140 
TMD0 F132L DEND and/or 
iDEND 
Yes Yes No het 34,1
33,1
34 
TMD0 F132V PNDM  -  - No het 133,
134 
TMD0 L135P iDEND  -  -  - het 141 













CL3(L0) E208K TNDM  - Yes  - het  38,1
42 





CL3(L0) D209N PNDM  -  - Yes het 134 




CL3(L0) Q211K PNDM  -  - Yes het 133,
134 
CL3(L0) D212I TNDMa  -  - Yes het 41,1
34 
CL3(L0) D212N TNDM  -  -  - het 41 
CL3(L0) D212E TNDM  -  -  - het 143 
CL3(L0) D212Y PNDM  - Yes Yes het 126,
144 
CL3(L0) L213R PNDMa Yes Yes Yes het 33,1
45 
CL3(L0) L213P iDEND 
and/or DEND 
 -  - Yes het 42,1
46 
CL3(L0) G214R Adult onset 
(MODY) 








CL3(L0) R216C TNDM  -  -  - het 99 
CL3(L0) V222M Adult onset 
(MODY) 








CL3(L0) T229N PNDM  -  - Yes het 99 





CL3(L0) T229I TNDM  -  - Yes hom 134,
141 
 33
CL3(L0) P254S PNDM  - Yes  - hom 144 





CL3(L0) A269D NDM  -  -  - het 142 
TMD1 G296R TNDM  - Yes  - het 132,
143 




TMD1 R306H NDMa  -  -  - het 141 
TMD1 V324M TNDM/PNDM  - Yes  - het  38,4
1 








TMD1 E350D TNDM  -  -  - het 148 
TMD1 A355T PNDM  -  - Yes het 42 
TMD1 E382V PNDM  -  - Yes hom 149 
TMD1 E382K PNDM  -  -  - hom 133 
TMD1 I395F TNDM  -  - No het 150 
TMD1 D424V NDM  -  - Yes het 151 
TMD1 C435R TNDMa  -  -  - het 33 




TMD1 L451P NDM  -  -  - het 41 
TMD1 S459R TNDM  -  -  - het 43 
TMD1 Q485R MODY  -  - Yes het 140 
TMD1 Q485H PNDMa  -  -  - het 122 
TMD1 T488I TNDM/PNDM  -  - Yes het 152 
TMD1 S532G TNDM  -  -  - het 153 
TMD1 F536L NDM  -  -  - het 102 
TMD1 I544T NDM  -  - Yes het 97 
TMD1 F577L PNDM  -  - Yes het 154 
TMD1 L582V TNDM  - Yes  - het 33,5
1 
TMD1 I585T TNDM  -  -  - het 136 
TMD1 V587G iDEND  -  - Yes het 155 
TMD1 T588I TNDM  -  -  - het 107 
 34
TMD1 V607M PNDM/Adult 
onset 
(MODY) 
 -  -  - het  99,1
56 




TMD1 R653Q TNDMa  - n.s.  - het 144 




TMD1 E747X PNDMb  -  - Yes hom 157 
CL6 
(NBD1) 
H817R PNDM   -  -  - het 158 
CL6 
(NBD1) 






G832C TNDM  -  - Yes het 99 
CL6 
(NBD1) 
G833D TNDM  -  -  - het 149 
CL6 
(NBD1) 
H863Y NDM  -  - Yes het 159 
CL6 
(NBD1) 
R878Q TNDM  -  -  - het 150 
CL6 
(NBD1) 
D898V NDM  -  - Yes het 160 
CL6 
(NBD1) 
R993C PNDM  - n.s. Yes het 144 
TMD2 H1024R PNDM  -  - Yes hom 161 
TMD2 H1024Y TNDM No Yes  - het 33,5
1 
TMD2 F1068I PNDM  -  - Yes hom 162 
TMD2 N1123D PNDM  -  -  - het 103 
TMD2 F1164L iDEND  -  - Yes hom 149,
163 
TMD2 Y1176C TNDM  -  - Yes het 164 
TMD2 F1177L TNDM  -  -  - het 99 
TMD2 Q1179R TNDM,       
Adult onset 
 - Yes Yes het 165,
166 
TMD2 F1182S TNDM  -  -  - het 167 




TMD2 R1183W PNDMa  -  - Yes het 41,9
9,13
4 
TMD2 A1185E PNDM  -  -  - hom 133 
TMD2 P1199L PNDM  - Yes Yes het 99,1
68 
TMD2 Q1225H PNDM  - n.s.  - het 144 
TMD2 N1245D Adult onset 
(MODY) 
 -  - Yes het 140 
TMD2 G1256S TNDM  -  - Yes het 150 







PNDM  -  - Yes het 169 






R1314H TNDM  -  - Yes het 141 
CL9 
(NBD2) 




















R1380S NDM  -  -  - het 102 
CL9 
(NBD2) 




F1393V NDM  -  -  - het 92 
CL9 
(NBD2) 














I1425V PNDM No Yes Yes het 33 
CL9 
(NBD2) 
A1458T Adult onset 
(MODY) 
 -  - Yes het 170 
CL9 
(NBD2) 




E1507D TNDM  - Yes  - het 37 
CL9 
(NBD2) 














V1523L Adult onset 
(MODY) 
 -  - Yes het 140 
CL9 
(NBD2) 
V1524M PNDM  -  -  - het 142 
CL9 
(NBD2) 
A1537P PNDMa  -  - Yes het 171 
 
Mutations in SUR1 associated with neonatal diabetes mellitus. TMD0, TMD1 and TMD2 
indicate transmembrane domains 0, 1 and 2. L0, intracellular loop 3. CL6 and CL9, 
intracellular loops 6 and 9 (which contain NBD1 and NBD2). The effects on channel activity, 
determined from electrophysiology, are indicated where known. A decrease in MgATP 
inhibition could be due to a reduction in ATP block at Kir6.2, or enhanced activation by 
SUR1. Heterozygous, homozygous and compound heterozygous mutations are indicated. 
Note that ABCC8 loss-of-function mutations that cause hyperinsulinaemic hyperglycaemia at 
birth and diabetes in later life are not included. Mutations are numbered according to the 
ABCC8 reference sequence NM_001287174.1. PNDM; permanent neonatal diabetes 
mellitus; TNDM, transient neonatal diabetes mellitus; NDM, neonatal diabetes mellitus; Adult 
onset, adult onset diabetes (where this is classified as maturity-onset diabetes of the young 
(MODY) is indicated); Po, open probability; SU, sulphonylurea; -, not tested or not known. a, 
indicates some patients show neurological features but were not diagnosed as either iDEND 
or DEND. b, it is unclear how a loss-of-function mutation produces sulphonylurea-sensitive 
neonatal diabetes mellitus but the authors hypothesize that this mutation results in 
production of an alternative splice variant with reduced ATP sensitivity.   
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Key points  
 
• KATP channels regulate insulin secretion from pancreatic ȕ-cells by closing in 
response to metabolically generated ATP. 
 
• Gain-of-function mutations in KATP channel subunits (Kir6.2 and SUR1) cause 
neonatal diabetes mellitus, whereas loss-of-function mutations cause hyperinsulinism 
of infancy.  
 
• Most (~90%) patients with neonatal diabetes mellitus can be treated with 
sulphonylurea drugs, which inhibit the hyperactivated KATP channels.  
 
• Atomic resolution structures of the KATP channel complex have identified the binding 
sites for nucleotides and sulphonylurea drugs and shed light on how disease-causing 
mutations produce their functional effects. 
 
• Functional and clinical studies have elucidated why some patients can transfer to 




Channel open probability. A measure of the fraction of the total recording time that an ion 
channel spends in its open state. An open probability of 1 indicates the channel is 
permanently open, and an open probability of 0 indicates the channel is always closed.  
 
Cryo-electron microscopy.  An electron microscopy method in which samples are cooled 
to cryogenic temperatures and embedded in vitreous water. It is widely used as an 
alternative to X-ray crystallography for determining the atomic structure of molecules, 
including ion channels. 
 
IC50. Concentration (for example, of ATP) at which channel inhibition is half-maximal.  
 
DEND syndrome. This syndrome is caused by KATP channel mutations that produce a 
severe reduction in channel sensitivity to ATP inhibition.  It is characterised by permanent 
neonatal diabetes mellitus, epilepsy, motor and mental development delay, and can be 
accompanied by features such as attention deficit hyperactivity disorder. 
 
FRET. Fluorescence-activated energy transfer describes the distance-dependent transfer of 
excitation energy from a fluorescent donor to a fluorescent acceptor that can be used for 
real-time imaging of the binding of a fluorescent ligand to a protein containing a 




Gain-of-function mutations in KATP channel subunits cause neonatal diabetes mellitus. This 
Review discusses the mechanism of action of mutations that lead to neonatal diabetes 
mellitus and briefly reviews work on the management of this disease. 
